Published online May 10, 2021.
https://doi.org/10.4070/kcj.2021.0104
The Role of Multimodality Imaging in Cardiac Sarcoidosis
Author's summary
Cardiac sarcoidosis (CS) is significantly associated with a poor prognosis due to the associated congestive heart failure, arrhythmias (such as an advanced atrioventricular block), and ventricular tachyarrhythmia. Novel imaging modalities are now available to detect CS lesions secondary to active inflammation, granuloma formation, and fibrotic changes such as 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) and cardiac magnetic resonance imaging (CMR). Systematic review revealed both modalities showed high sensitivity to detect CS, while FDG PET and CMR provide different aspects of the pathophysiology of CS.
Abstract
The etiology and the progression of sarcoidosis remain unknown. However, cardiac sarcoidosis (CS) is significantly associated with a poor prognosis due to the associated congestive heart failure, arrhythmias (such as an advanced atrioventricular block), and ventricular tachyarrhythmia. Novel imaging modalities are now available to detect CS lesions secondary to active inflammation, granuloma formation, and fibrotic changes. 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) and cardiac magnetic resonance imaging (CMR) play essential roles in diagnosing and monitoring patients with confirmed or suspected CS. The following focused review will highlight the emerging role of non-invasive cardiac imaging techniques, including FDG PET/CT and CMR.
INTRODUCTION
Sarcoidosis is a chronic multi-system inflammatory disorder of unknown etiology characterized pathologically by the formation of non-caseating granulomas in the involved organs or tissues. Essentially, any body tissue may be affected,1), 2) but the most commonly involved include the lymph nodes, skin, lung, musculoskeletal system, and eyes.
Although the overall prognosis of patients with systemic sarcoidosis is generally favorable, cardiac sarcoidosis (CS) is significantly associated with a poor prognosis due to congestive heart failure, arrhythmias (such as an advanced atrioventricular block), and ventricular tachyarrhythmia.3), 4) Thus, an early and precise diagnosis of CS is essential. Recent studies have demonstrated the usefulness of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) and cardiac magnetic resonance imaging (CMR) for assessing CS. In this review, we focus on the pathophysiology and diagnostic aspects of CS with multimodality imaging.
ETIOLOGY
The incidence of sarcoidosis and its cardiac involvement varies among ethnic groups and regions.5), 6) Symptomatic CS has been reported in up to 10% of the patients with systemic sarcoidosis.7), 8), 9), 10) An autopsy series from the United States and Japan showed that approximately 27% and 80% of patients with systemic sarcoidosis, respectively, had CS.11), 12) Recent advances in cardiac imaging tools have enabled the detection of asymptomatic CS.13) As such, imaging series have reported higher rates of cardiac involvement in patients with extra-CS, ranging from 19% to 55% for asymptomatic CS.4), 8), 13), 14), 15)
PATHOLOGICAL CHARACTERISTICS OF CARDIAC SARCOIDOSIS
The pathological hallmark of CS is the non-caseating epithelioid granuloma with a compact central area of macrophages and scattered lymphocytes.1) If there is active inflammation, the granuloma can progress to irreversible fibrosis.16) The myocardium of the left ventricular free wall is the most common location of sarcoid involvement, followed by the interventricular septum, papillary muscles, right ventricle, and atria.17), 18) An endomyocardial biopsy is a valuable tool in the definitive diagnosis of CS,19) but it is limited owing to its low sensitivity due to the patchy distribution of granulomas and its complications.
CLINICAL PRESENTATION
CS manifestations can range widely from a clinically asymptomatic form to sudden cardiac death.20) Arrhythmic, cardiomyopathic, and pericardial manifestations are common clinical signs and symptoms (Table 1).20), 21), 22), 23), 24), 25)
Table 1
Clinical presentations of cardiac sarcoidosis
Atrioventricular conduction disease due to the infiltration of sarcoid granulomas is the most common finding in patients with CS.26) Ventricular and atrial arrhythmias are also frequent manifestations, with the latter being caused by atrial dilation secondary to left ventricular dysfunction and the atrial infiltration of sarcoid granulomas. Both systolic and diastolic ventricular dysfunction can result from granulomatous inflammation and subsequent scarring, subsequently leading to heart failure. Meanwhile, pulmonary infiltration may lead to right ventricular failure. Less commonly, CS may manifest as progressive pericardial diseases, such as pericarditis or tamponade.
CRITERIA FOR THE DIAGNOSIS OF CARDIAC SARCOIDOSIS
CS is conventionally diagnosed by the appropriate combination of clinical and physiological signs and symptoms and multimodal imaging. Several diagnostic criteria have been proposed, and one commonly used is the Japanese Ministry of Health and Welfare criteria,27), 28) modified in 2015 by the Japanese Society of Sarcoidosis and Other Granulomatous Disorders (Table 2).25) The Heart Rhythm Society Expert Consensus Statement of the CS was also published in 2014 (Table 3).29) In these 2 criteria, the diagnosis is separated by histological and clinical methods. To confirm the histological diagnosis, the presence of non-caseating epithelioid granulomas from the endomyocardial biopsy sample should be demonstrated. The histological analysis of operative or endomyocardial biopsy specimens could be the gold standard. However, endomyocardial biopsy cannot be performed on all suspected regions and has a lower sensitivity in diagnosing CS.19) On the contrary, the clinical diagnosis correlates the histological diagnosis of extra-cardiac sarcoidosis with the electrocardiographic and imaging findings, including echocardiography, 67Ga scintigraphy, 18F-FDG PET, and late gadolinium enhancement on CMR.
18F-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY
PET is a highly sensitive and non-invasive molecular imaging technique that can visualize and quantify the active processes of physiological function and disease conditions, in contrast to anatomical approaches. 18F-FDG is a glucose analog widely used to visualize and quantify glucose metabolism in the target region since it is taken up by plasma membrane glucose transporters (GLUT) in living cells and phosphorylated by intracellular hexokinase into 18F-FDG-6-phosphate (18F-FDG-6-P) similar to glucose. 18F-FDG-6-P is retained within the cell without further metabolism along the glycolytic pathway, a phenomenon known as metabolic trapping. Therefore, tissue activity can be directly visualized using 18F-FDG PET.
Cardiac metabolism and preparation to suppress the physiological 18F-fluorodeoxyglucose uptake
Under normal conditions, free fatty acids (FFAs) and glucose are the major energy sources for cardiac metabolism. Since the 18F-FDG is an analog of glucose, its physiological accumulation in the myocardium has a causal influence on the false-positive diagnosis of CS.30) The fasting state has a significant effect on the physiological uptake. Figure 1 shows a representative case of various physiological uptakes during follow-up in one patient (non-CS case). Under long fasting conditions, glucose production and glucose oxidation decrease, leading to the release of available FFA from adipose tissue to provide an alternative energy source. The physiological uptake of 18F-FDG in the myocardium can be suppressed with a low-carbohydrate diet and a high-fat diet due to the switch to FFA metabolism. As such, FFA level is an important marker of physiological 18F-FDG uptake suppression.31)
Figure 1
A representative case of various physiological myocardial uptake patterns during follow-up in one patient.
A patient with malignant lymphoma underwent serial 18F-fluorodeoxyglucose positron emission tomography/computed tomography scans for follow-up after chemotherapy. Focus on the left ventricular uptake, no uptake (A), diffuse strong uptake with left ventricular uptake (B), predominant regional uptake in the base of the myocardium (C), and diffuse uptake (D) is pointed out.
18F-fluorodeoxyglucose accumulation in sarcoidosis lesion
The significant 18F-FDG accumulation in sarcoidosis lesions is caused by activated inflammatory cells, such as neutrophils, macrophages, and lymphocytes; GLUT1 and GLUT3 in the cell membrane; and hexokinase.32), 33) As 18F-FDG uptake reflects active inflammation, it is therefore useful in detecting CS and guiding immunosuppression management.34) Figure 2 shows a representative case of CS before and after steroid therapy.
Figure 2
A representative case of a woman in her 60s with complete right bundle branch block before and after steroid therapy. Cardiac magnetic resonance shows subepicardial gadolinium enhancement at the basal septum and lateral wall (A). Focal myocardial fluorodeoxyglucose uptake at the septum and multiple uptake at the mediastinal lymph nodes are consistent with cardiac sarcoidosis (B). After administration of steroid therapy, myocardial and mediastinal uptake are diminished (C).
Myocardial 18F-FDG uptake patterns are conventionally divided into 4 groups: none, diffuse, focal, and focal on diffuse.35), 36) When myocardial 18F-FDG uptake is absent, it is negative for active CS lesions. Definite diffuse 18F-FDG uptake in the entire left ventricular wall is generally a physiological uptake and does not indicate an abnormality. On the contrary, focal and focal on diffuse 18F-FDG uptake in the left ventricular wall are considered positive for CS. In addition, the diffuse at base uptake pattern is known to be associated with inadequate physiologic suppression.37)
The combination of 18F-FDG and perfusion findings has led to improvements in the accurate diagnoses and prognostication.3)
With its high diagnostic value and high inter-rater reproducibility, 18F-FDG PET texture analysis can also be used to diagnose CS, focusing on its heterogeneous distribution.38) Texture analysis can differentiate abnormal and physiological CS uptake.
CARDIAC MAGNETIC RESONANCE IMAGING
Late gadolinium enhancement
CMR offers both functional and structural information to help detect the acute and chronic inflammatory phases of CS. In contrast, it does not require specific preparation such as long fasting before examination as required for 18F-FDG PET; however, it is contraindicated in patients with MR unsafe or some MR conditional implantable devices.
CMR with late gadolinium enhancement (LGE) is an emerging tool for evaluating CS. Mid-wall or subepicardial LGE in the basal ventricular wall, lateral wall, and septum (Figure 2) is the most common pattern seen in CS,4) recently confirmed in a meta-analysis of studies with histological confirmation.39)
Myocardial enhancement on LGE-CMR images adds an independent prognostic value for the risk stratification sarcoidosis patients.40), 41) Greulich et al.8) also reported that the presence of LGE was the best independent predictor of death and other adverse events in CS. However, it is difficult to differentiate active inflammation from chronic fibrosis using LGE alone.
T1/T2 mapping
CMR mapping techniques such as T1, T2, and extracellular volume can provide additional quantitative information regarding interstitial changes. In combination with LGE, CMR mapping can significantly improve the diagnosis of subclinical CS.42) Greulich et al.43) compared 61 patients with sarcoidosis and 26 healthy patients and found that the former had significantly higher native T1, T2, and extracellular volume. The weighted mean T1 value at 1.5 T of 994 ms (range, 975–1,039 ms) in the patients with sarcoidosis was significantly higher than the controls (960 ms; range, 942–986 ms), independent of the presence of LGE. Meanwhile, the patients with sarcoidosis had a weighted mean T2 value at 1.5 T of 52.3 ± 3.8 ms, higher than the 49.0 ± 1.6 ms in the controls. At 3 T, the values were 54.0 ± 12.2 ms and 45.0 ± 10.8 ms, respectively.44) Figure 3 shows active CS with LGE-CMR and T2 mapping, which correlate with positive 18F-FDG PET findings. T2 mapping provides an absolute and objective parameter for active inflammation. Native T1 and T2 mapping could be used for disease monitoring and differentiating sarcoid patients from healthy controls without the use of gadolinium.45)
Figure 3
A woman in her 60s was admitted to the hospital with acute heart failure. Cardiac magnetic resonance imaging shows abnormal gadolinium enhancement with transmural and epicardium distribution of left ventricle (A, arrows). Through T2 mapping, the diffuse prolongation of T2 values is observed, suggesting myocardial edema or inflammation due to active cardiac sarcoidosis (B, normal range was under 54 ms). 18F-fluorodeoxyglucose positron emission tomography/computed tomography reveals correlated focal uptake, confirming active cardiac sarcoidosis (C, arrows).
Strain imaging
Myocardial strain analysis has been developed to objectively evaluate the regional myocardial function, including longitudinal, circumferential, radial, and rotational myocardial strains.46) Among these, left ventricular global longitudinal strain (GLS) has been receiving the most attention because subendocardial fibers originate longitudinally and thus, may be sensitive in detecting early changes in various cardiomyopathies. Two-dimensional speckle tracking echocardiography has been used to evaluate CS. GLS and global circumferential strain were significantly lower in extra-cardiac sarcoidosis patients despite not exhibiting any cardiac symptoms.47) Impaired GLS is associated with major cardiac events in patients with CS.47) Due to its association with cardiac events in patients with sarcoidosis, a recent study also reported that biventricular strain deterioration can be used as an early marker of cardiac involvement.48)
Similar to speckle tracking echocardiography, CMR techniques for assessing myocardial strain, such as tagging,49) strain-encoded (SENC) magnetic resonance imaging (MRI),50), 51) and myocardial feature-tracking deformation imaging (FTI),52) have the potential to detect a wide range of myocardial diseases early, accurately, and without the need for contrast agent injection. A small study using SENC for CS has been reported.53) Specifically, FTI is also useful for evaluating regional and global strains, well correlated with SENC MRI.54) This method requires only cine images without specific extra scanning. Dabir et al.55) reported that GLS assessed with FTI was reduced in patients with a negative outcome, possibly serving as a marker for early cardiac involvement in sarcoidosis. Figure 4 shows a case of positive LGE and 18F-FDG PET with FTI evaluation. In this case, regional deformation due to aneurysmal formation was visualized well with FTI.
Figure 4
CMR = cardiac magnetic resonance imaging; FDG = fluorodeoxyglucose.
A man in his 40s was diagnosed as systemic sarcoidosis by transbronchial lung biopsy.
Due to complete right bundle branch block and diffuse left ventricular dysfunction, he was referred for CMR. Left ventricular 2-chamber view of the late gadolinium enhanced CMR shows hyperenhancement at the inferior wall (A, yellow arrows). After a long fast with a low-carbohydrate diet, the 18F-FDG positron emission tomography/computed tomography reveals abnormal FDG uptake at the inferior wall, indicating active cardiac sarcoidosis (B). (C and D) Feature-tracking using cine magnetic resonance imaging for longitudinal strain clearly depicts regional wall motion abnormality with aneurysmal deformation of the mid-inferior wall (green strain curve).
An autopsy study reported that aneurysm formation was present in 8% of patients with cardiac sarcoidosis,18) the combination of CMR and 18F-FDG PET could help differentiate left ventricular aneurysm due to CS from myocardial infarction.
DIAGNOSTIC ABILITY
Systematic reviews about the diagnostic ability of 18F-FDG PET and CMR are summarized in Tables 4, 5, 6.56), 57), 58), 59), 60), 61), 62), 63), 64), 65), 66), 67), 68), 69), 70), 71), 72), 73), 74), 75), 76), 77), 78), 79), 80), 81), 82), 83), 84), 85), 86), 87), 88), 89), 90), 91), 92), 93), 94), 95), 96), 97), 98), 99), 100), 101), 102), 103), 104), 105), 106), 107), 108), 109), 110), 111) The sensitivity of 18F-FDG PET in the diagnosis of CS ranges from 27% to 100%, depending on disease activity since it can only detect active lesions. CMR has a similar sensitivity in detecting CS (range, 28%–100%). Importantly, 18F-FDG PET and CMR provide different aspects of the pathophysiology of CS.108) Therefore, both modalities are recommended for patients who meet the following criteria: (1) equivocal or negative CMR findings in the setting of high clinical suspicion; (2) CMR findings with highly probable CS. In such cases, 18F-FDG PET may identify inflammation/potential role for immunosuppressive therapies. The suggested algorithm for diagnosis is CMR. If LGE is negative, the patient's prognosis would be excellent. However, if LGE is positive or inconclusive, the disease activity should be evaluated using 18F-FDG PET for immunosuppressive therapy.
Table 4
Diagnostic performance of 18F-FDG PET and 18F-FDG PET/CT to detect cardiac involvement in patients with sarcoidosis
Table 5
Diagnostic performance of CMR to detect cardiac involvement in patients with sarcoidosis
Table 6
Diagnostic performance CMR in combination with FDG PET to detect cardiac involvement in patients with sarcoidosis
COMPUTED TOMOGRAPHY
The disadvantage of MRI is that it is contraindicated for patients with MR unsafe implantable devices or implantable devices. In patients with non-ischemic cardiomyopathy unable to undergo CMR, cardiac computed tomography (CT) can also be used to perform delayed enhancement imaging.112) CT may be advantageous due to its comprehensive systemic evaluation of sarcoidosis. After whole-body scanning, a delayed cardiac scan could be consequently performed even in patients with implantable devices. We reported that the image quality of delayed iodine contrast-enhanced CT (DE-CT) sufficiently allows for the assessment of hyper-enhanced myocardium in patients with or without implantable devices.102), 113) DE-CT can also delineate the extent of CS with an accuracy comparable to that of LGE-CMR. 102)
Figure 5 shows a representative case before and after implantation of a cardioverter-defibrillator following DE-CT. Since the contrast noise ratio of DE-CT was relatively lower than CMR, reader experience is required to visually assess the DE-CT results. As observed in 18F-FDG PET,38) objective texture analysis of myocardial DE-CT showed a similar diagnostic value and higher reproducibility for differentiating between CS and non-CS patients compared to visual assessment.114)
Figure 5
Arrhythmia was detected in a woman in her 50s. Abnormal enhancement and uptake are shown in the left ventricular lateral wall with late gadolinium enhancement of CMR and 18F-fluorodeoxyglucose positron emission tomography/computed tomography (A and B, arrows). DE-CT also highlights the abnormal enhancement in the lateral wall, seen in the CMR (C, arrows). The patient was diagnosed with active cardiac sarcoidosis and was implanted with an ICD to prevent ventricular tachycardia. DE-CT after ICD implantation reveals abnormal enhancement in the lateral wall, as seen previously (D, arrows). Although there were metal artifacts mainly at the septum due to the ICD leads, we were able to compare the 2 images and confirm that the lesion was not worsening over time.
CMR = cardiac magnetic resonance imaging; DE-CT = delayed iodine contrast-enhanced computed tomography; ICD = implantable cardioverter-defibrillator.
CONCLUSION
CS remains a morbid and potentially fatal manifestation of sarcoidosis. Though the diagnosis of CS is still challenging, 18F-FDG PET and CMR are promising tools that may help us improve the diagnosis and understanding of the pathophysiology of CS.
Funding:This study was supported by grants from the Japan Society for the Promotion of Science (JSPS) KAKENHI # 20K08042 (NOM), Kondou Kinen Medical Foundation (TA), and Nakatani Foundation for Advancement of Measuring Technologies in Biomedical Engineering (TA).
Conflict of Interest:Dr. Noriko Oyama-Manabe has activities as consultant for Canon Medical Systems; also, she got payment for lectures from Daiichi-Sankyo, Philips Medical Systems, Eisai, Bayer Healthcare, GE Healthcare, Nihon Medi-Physics, Co., Ltd. and Canon Medical Systems.
Data Sharing Statement:The data generated in this study is available from the corresponding authors upon reasonable request.
Author Contributions:
Conceptualization: Oyama-Manabe N.
Data curation: Oyama-Manabe N, Aikawa T, Tsuneta S.
Formal analysis: Oyama-Manabe N, Aikawa T.
Funding acquisition: Oyama-Manabe N.
Investigation: Oyama-Manabe N, Manabe O.
Methodology: Oyama-Manabe N, Manabe O, Aikawa T.
Project administration: Oyama-Manabe N, Manabe O, Aikawa T.
Resources: Oyama-Manabe N, Manabe O, Aikawa T, Tsuneta S.
Software: Manabe O, Aikawa T, Tsuneta S.
Supervision: Oyama-Manabe N, Manabe O.
Validation: Tsuneta S.
Visualization: Aikawa T, Tsuneta S.
Writing - original draft: Oyama-Manabe N.
Writing - review & editing: Oyama-Manabe N, Manabe O.
References
-
Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999;16:149–173.
-
-
Iwai K, Tachibana T, Takemura T, Matsui Y, Kitaichi M, Kawabata Y. Pathological studies on sarcoidosis autopsy. I. Epidemiological features of 320 cases in Japan. Acta Pathol Jpn 1993;43:372–376.
-
-
Hulten E, Aslam S, Osborne M, Abbasi S, Bittencourt MS, Blankstein R. Cardiac sarcoidosis-state of the art review. Cardiovasc Diagn Ther 2016;6:50–63.
-
-
Houston BA, Mukherjee M. Cardiac sarcoidosis: clinical manifestations, imaging characteristics, and therapeutic approach. Clin Med Insights Cardiol 2014;8:31–37.
-
-
Fleming HA, Bailey SM. Sarcoid heart disease. J R Coll Physicians Lond 1981;15:245–246. 249–253.
-
-
Hiraga H, Iwai K, Hiroe M, Omori F, Sekiguchi M, Tachibana T. In: Guidelines for diagnosis of cardiac sarcoidosis: study report on diffuse pulmonary diseases [in Japanese]. Tokyo: The Japanese Ministry of Health and Welfare; 1993. pp. 23-24.
-
-
Diagnostic standard and guidelines for sarcoidosis. Jpn J Sarcoidosis Granulomatous Disord 2007;27:89–102.
-
-
Manabe O, Yoshinaga K, Ohira H, et al. The effects of 18-h fasting with low-carbohydrate diet preparation on suppressed physiological myocardial 18F-fluorodeoxyglucose (FDG) uptake and possible minimal effects of unfractionated heparin use in patients with suspected cardiac involvement sarcoidosis. J Nucl Cardiol 2016;23:244–252.
-
-
Yamada S, Kubota K, Kubota R, Ido T, Tamahashi N. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med 1995;36:1301–1306.
-
-
Mochizuki T, Tsukamoto E, Kuge Y, et al. FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. J Nucl Med 2001;42:1551–1555.
-
-
Yoshinaga K, Manabe O, Ohira H, Tamaki N. Focus issue on cardiac sarcoidosis from international congress of nuclear cardiology and cardiac CT (ICNC 12) symposium: improving the detectability of cardiac sarcoidosis—practical aspects of 18F-fluorodeoxyglucose positron emission tomography imaging for diagnosis of cardiac sarcoidosis—. Annals of Nuclear Cardiology 2015;1:87–94.
-
-
Okasha O, Kazmirczak F, Chen KA, Farzaneh-Far A, Shenoy C. Myocardial involvement in patients with histologically diagnosed cardiac sarcoidosis: a systematic review and meta-analysis of gross pathological images from autopsy or cardiac transplantation cases. J Am Heart Assoc 2019;8:e011253
-
-
Hulten E, Agarwal V, Cahill M, et al. Presence of late gadolinium enhancement by cardiac magnetic resonance among patients with suspected cardiac sarcoidosis is associated with adverse cardiovascular prognosis: a systematic review and meta-analysis. Circ Cardiovasc Imaging 2016;9:e005001
-
-
Nakano S, Kimura F, Osman N, et al. Improved myocardial strain measured by strain-encoded magnetic resonance imaging in a patient with cardiac sarcoidosis. Can J Cardiol 2013;29:1531.e9–1531.11.
-
-
Yamagishi H, Shirai N, Takagi M, et al. Identification of cardiac sarcoidosis with 13N-NH3/18F-FDG PET. J Nucl Med 2003;44:1030–1036.
-
-
Okumura W, Iwasaki T, Toyama T, et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 2004;45:1989–1998.
-
-
Varghese M, Smiley D, Bellumkonda L, Rosenfeld LE, Zaret B, Miller EJ. Quantitative interpretation of FDG PET for cardiac sarcoidosis reclassifies visually interpreted exams and potentially impacts downstream interventions. Sarcoidosis Vasc Diffuse Lung Dis 2018;35:342–353.
-
-
Divakaran S, Stewart GC, Lakdawala NK, et al. Diagnostic accuracy of advanced imaging in cardiac sarcoidosis. Circ Cardiovasc Imaging 2019;12:e008975
-
-
Furuya S, Naya M, Manabe O, et al. 18F-FMISO PET/CT detects hypoxic lesions of cardiac and extra-cardiac involvement in patients with sarcoidosis. J Nucl Cardiol. 2019[Epub ahead of print].
-
-
Sgard B, Brillet PY, Bouvry D, et al. Evaluation of FDG PET combined with cardiac MRI for the diagnosis and therapeutic monitoring of cardiac sarcoidosis. Clin Radiol 2019;74:81.e9–81.18.
-
-
Higashi H, Inaba S, Iio C, et al. Features and clinical impact of extra-cardiac lesions with 18F-fluorodeoxyglucose positron emission tomography in patients with suspected cardiac sarcoidosis. Int J Cardiol Heart Vasc 2020;30:100587
-
-
Miller RJ, Cadet S, Pournazari P, et al. Quantitative assessment of cardiac hypermetabolism and perfusion for diagnosis of cardiac sarcoidosis. J Nucl Cardiol. 2020[Epub ahead of print].
-
-
Okune M, Yasuda M, Soejima N, et al. Diagnostic utility of fusion 18F-fluorodeoxyglucose positron emission tomography/cardiac magnetic resonance imaging in cardiac sarcoidosis. J Nucl Cardiol. 2020
-
-
Matsumoto K, Ehara S, Sakaguchi M, et al. Clinical characteristics of late gadolinium enhancement in patients with cardiac sarcoidosis. Osaka City Med J 2015;61:9–17.
-
-
Komada T, Suzuki K, Ishiguchi H, et al. Magnetic resonance imaging of cardiac sarcoidosis: an evaluation of the cardiac segments and layers that exhibit late gadolinium enhancement. Nagoya J Med Sci 2016;78:437–446.
-
-
Smedema JP, van Geuns RJ, Truter R, Mayosi BM, Crijns HJ. Contrast-enhanced cardiac Magnetic Resonance: distinction between cardiac sarcoidosis and infarction scar. Sarcoidosis Vasc Diffuse Lung Dis 2017;34:307–314.
-
-
Ghanizada M, Rossing K, Bundgaard H, Gustafsson F. Clinical presentation, management and prognosis of patients with cardiac sarcoidosis. Dan Med J 2018;65:A5462.
-
-
Darlington P, Gabrielsen A, Cederlund K, et al. Diagnostic approach for cardiac involvement in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2019;36:11–17.
-
-
Russo JJ, Nery PB, Ha AC, et al. Sensitivity and specificity of chest imaging for sarcoidosis screening in patients with cardiac presentations. Sarcoidosis Vasc Diffuse Lung Dis 2019;36:18–24.
-
-
Narula J, Chandrashekhar Y, Ahmadi A, et al. SCCT 2021 expert consensus document on coronary computed tomographic angiography: a report of the Society of Cardiovascular Computed Tomography. J Cardiovasc Comput Tomogr 2020:S1934-5925(20)30473-1.
-